We are proud to announce that AGILeBiotics is the winner of the Investors Forum 2019, which took place at the Dutch Life Sciences Conference in Leiden on November 28th. During the conference AGILeBiotics has introduced its drug pipeline emphasizing the pre-clinical candidate TOFRAMICIN, a novel antibiotic candidate in development against multidrug-resistant Gram-negative and Gram-positive bacterial infections. With our plenary pitch, we have successfully reached out to potential co-investors in order to close the Series A round in near future. The investment will bring TOFRAMICIN into clinical development and closer to patients suffering from deadly hospital-acquired infections.